Company Performance Metrics
Myer Herszberg: Chairman and Founder- Sarah Valle: Chief Development Officer and Co-founder
Clinical stage bio-pharma company focused on the treatment of mucin-containing and secreting cancers. Bromelain and acetylcysteine, BromAc™, is a patented combination drug developed by our team for mucinous cancers, where the drug affects glycosidic linkages and disulphide bonds in glycoproteins including mucinous tumours. Bromelain is an enzyme
extracted from pineapple stem or fruit (ananas comosus) and it is made up of a number of enzymes (proteases, carbohydrases, phosphatases, peroxidases, etc.) that gives it unique enzymatic properties for the hydrolysis of glycosidic bonds in complex carbohydrates. As a therapeutic molecule, it is currently used as a mucolytic in combination with acetylcysteine with anticancer properties for the treatment of mucinous tumours. It combines synergistically with a variety of anticancer drugs.
